医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Cell Signaling Technology Wins “Best Antibodies” and “Most Useful Website” at The Life Science Industry Awards

2014年11月22日 AM12:31
このエントリーをはてなブックマークに追加


 

WASHINGTON

Cell Signaling Technology, a leading provider of antibodies, kits and services, announced today that it has won two Life Science Industry Awards® for “Best Antibodies” and “Most Useful Website.” Hosted by BioInformatics LLC, the awards were announced at a ceremony in Washington, DC on November 18, 2014, in conjunction with the Society for Neuroscience Annual Meeting.

CST is dedicated to developing antibodies that align with the needs of the research community. In this way, CST is able to continually generate relevant, validated antibodies and informative website content to help drive research forward.

Presented to the world’s top performing life science suppliers in 28 categories, the Life Science Industry Awards are recognized as a benchmark of excellence in the life science tools industry. Voted by BioInformatics LLC’s online network of scientists, The Science Advisory Board, over 3,000 individuals from 76 different countries participated in the nomination process. The Life Science Industry Awards are unique in that they bring the voice of the customer into the voting process and are backed up by rigorous scoring methodology, which bring these awards the highest degree of integrity.

“I think as a company, our primary mission, really, is to continue to push forward the frontiers of our knowledge. We want to support the research community and allow it — enable it — empower it — to make new discoveries. So, to have our efforts recognized by the research community with this award is quite an honor,” said Michael J. Comb, PhD., CST President and CEO.

About CST
Founded by research scientists in 1999, CST is a private, family-owned company with over 400 employees worldwide. Active in the field of applied systems biology research, particularly as it relates to cancer, CST understands the importance of using antibodies with high levels of specificity and lot-to-lot consistency. We produce all of our antibodies in house, and perform painstaking validations for multiple applications. Technical support is provided by the same CST scientists who produce our antibodies, helping customers design experiments, troubleshoot, and achieve reliable results. CST is certified by BSI to be compliant with ISO 9001:2008 for the design, development, and production of monoclonal antibodies.

To find out more, visit the www.cellsignal.com.

*For research use only. Not for use in diagnostic procedures.

Cell Signaling Technology®, CST™ are trademarks of Cell Signaling Technology, Inc.
Life Science Industry Awards® is a registered trademark of Bioinformatics, LLC.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20141121005535/en/

CONTACT

Cell Signaling Technology, Inc.
Rebecca J. Reppucci, MBA,
978-867-2300 x2127
Director of Marketing Communications
marketingpr@cellsignal.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作